Do omega-3 and omega-6 fatty acids compete in ways that affect inflammation, platelet signaling, and lipoprotein function?

Biochemical mechanisms of fatty acid competition

• Membrane competition: Omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) compete directly for a finite number of incorporation sites (specifically the sn-2 position) within cell membrane phospholipids. Shifting the dietary or serum ratio toward omega-3s (EPA/DHA) displaces arachidonic acid (AA, an omega-6), directly remodeling membrane fluidity and microdomain organization.
• Enzymatic pathways: Both pathways rely on a shared, rate-limiting suite of metabolic enzymes. Upstream, the parent fatty acids (ALA and LA) compete for desaturases ($\Delta$5-desaturase/FADS1 and $\Delta$6-desaturase/FADS2) and elongases. Downstream, liberated long-chain PUFAs compete directly for active sites on cyclooxygenase (COX-1/COX-2) and lipoxygenase (LOX) enzymes.

Downstream physiological effects

• Inflammation resolution: The membrane EPA-to-AA ratio determines the available precursor pool for lipid mediators. High AA levels favor pro-inflammatory eicosanoids (e.g., PGE2, LTB4). Conversely, enriching membranes with EPA and DHA drives the synthesis of specialized pro-resolving mediators (SPMs), such as E-series and D-series resolvins, which actively terminate inflammatory cascades.
• Platelet signaling: COX and LOX enzymes convert AA into thromboxane $A_2$ ($\text{TXA}_2$), a highly potent promoter of platelet aggregation and vasoconstriction. When EPA levels are elevated, substrate competition shifts production toward the significantly less active thromboxane $A_3$ ($\text{TXA}_3$) and vasodilatory prostacyclins ($\text{PGI}_3$), attenuating platelet activation and aggregation.
• Lipoprotein function: High-density lipoprotein (HDL) serves as a major carrier for PUFAs and SPM precursors. When the enzymatic balance is shifted toward pro-resolving pathways, HDL particle quality and its native vascular-protective capabilities—such as cholesterol efflux capacity and anti-inflammatory activity—are preserved. Additionally, healthy, functional HDL directly suppresses platelet activation and inhibits agonist-stimulated $\text{TXA}_2$ production.

Bottom line

An imbalance in the omega-6 to omega-3 ratio directly compromises inflammation resolution, increases platelet aggregability, and impairs lipoprotein function. This occurs because both fatty acid families must compete for the same membrane incorporation sites and shared desaturase, elongase, COX, and LOX enzymes.